Salvianolic acid A inhibits the activation and aggregation of platelets in patients with acute coronary syndrome.
The acute blockage in coronary arteries further causes acute coronary syndrome (ACS). There are 2 main factors implicated in the activation and aggregation of platelets. However, this present study aimed to investigate the effect of salvianolic acid A (SAA) on the platelets in patients with ACS and explore its potential mechanism of action.
The impact of SAA on platelets under different stimulation conditions was studied using flow cytometry and platelet aggregation detection techniques.
The results demonstrated that in 40 ACS patients, ex vivo treatment of platelets with SAA (0.1 mg/ml) significantly reduced aggregation and activation. Intriguingly, we found no significant difference between the 3 types of ACS patients in the antiplatelet effect of SAA. Moreover, the results indicated that C-reactive protein, alanine aminotransferase, C-reactive protein-to-albumin ratio, total cholesterol, and low-density lipoprotein levels were negatively correlated with the anti-platelet effect of SAA in ACS patients and that a history of smoking may reduce the anti-platelet effect of SAA in the same group.
In summary, the above findings of this study highlight the therapeutic potential of SAA against platelets in patients with ACS, providing new insights into clinical treatment and experimental research.
The impact of SAA on platelets under different stimulation conditions was studied using flow cytometry and platelet aggregation detection techniques.
The results demonstrated that in 40 ACS patients, ex vivo treatment of platelets with SAA (0.1 mg/ml) significantly reduced aggregation and activation. Intriguingly, we found no significant difference between the 3 types of ACS patients in the antiplatelet effect of SAA. Moreover, the results indicated that C-reactive protein, alanine aminotransferase, C-reactive protein-to-albumin ratio, total cholesterol, and low-density lipoprotein levels were negatively correlated with the anti-platelet effect of SAA in ACS patients and that a history of smoking may reduce the anti-platelet effect of SAA in the same group.
In summary, the above findings of this study highlight the therapeutic potential of SAA against platelets in patients with ACS, providing new insights into clinical treatment and experimental research.
Authors
Wang Wang, Zhang Zhang, Li Li, Xie Xie, Mei Mei, Zhang Zhang, Mamun Mamun, Lu Lu, Liang Liang, Zeng Zeng
View on Pubmed